iBio, Inc.
For the period ended Jun 30, 2026. Filed Aug 28, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Aug 28, 2026
IBIO$0.80+7.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
The required information is incorporated by reference from our definitive proxy statement to be filed with the SEC relating to our 2026 Annual Meeting, including, but not necessarily limited to, the sections entitled “Executive Compensation” and “Director Compensation for 2026 Fiscal Year.”
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.